No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies
- 12 July 2021
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (5) , 606-615
Abstract
Summary: Background: In 2019, the United States Food and Drug Administration detected above‐regulation levels of the human carcinogen N‐nitrosodimethylamine (NDMA) in ranitidine, resulting in a complete removal of the medication from the market. NDMA is known to cause gastrointestinal malignancies in animal models.Aim: To determine if patients who were receiving ranitidine have a higher risk of developing cancers of the digestive tract compared to patients taking other anti‐reflux medications.Methods: Using the nationwide database IBM Explorys, patients taking ranitidine were compared to patients on either famotidine or omeprazole. Incidence data of new malignancies of the oesophagus, stomach, liver, pancreas, and colon/rectum were obtained in 1‐year intervals for up to 10 years. Two multivariable logistic regression models were used to calculate odds ratios (ORs), one adjusting for common risk factors for each cancer studied, and the other for demographic factors.Results: Patients on ranitidine who were compared to patients on famotidine had ORs of 0.51(95% CI 0.43‐0.60), 0.43(95% CI 0.36‐0.51), 0.39(95% CI 0.36‐0.41), 0.54(95% CI 0.49‐0.62), and 0.46(95% CI 0.43‐0.49) of developing oesophageal, gastric, hepatocellular, pancreatic, and colorectal cancers, respectively (P < 0.001). Patients on ranitidine compared to omeprazole had ORs of 0.62(95% CI 0.52‐0.72), 0.58(95% CI 0.49‐0.68), 0.81 (95% CI 0.76‐0.86), 0.68(95% CI 0.60‐0.76), and 0.66(95% CI 0.62‐0.70) of developing oesophageal, gastric, hepatocellular, pancreatic, and colorectal cancers respectively (P < 0.001).Conclusions: Use of ranitidine was not associated with an increased odds of developing gastrointestinal malignancies compared to omeprazole or famotidine use.Keywords
This publication has 24 references indexed in Scilit:
- Gastro-Oesophageal Reflux DiseaseDrugs, 2011
- N -Nitrosodimethylamine (NDMA) as a Drinking Water Contaminant: A ReviewEnvironmental Engineering Science, 2003
- Metabolism of azoxymethane, methylazoxymethanol and N-nitrosodimethylamine by cytochrome P450IIE1Carcinogenesis, 1991
- The effectiveness of ranitidine in reducing gastric acid‐secretion decreases with continued therapy.British Journal of Clinical Pharmacology, 1986
- Carcinogenesis in rats by nitrosodimethylamine and other nitrosomethylalkylamines at low dosesCancer Letters, 1984
- Ranitidine: A New H2-Receptor AntagonistNew England Journal of Medicine, 1983
- Genotoxic effects in rodents given high oral doses of ranitidine and sodium nitriteCarcinogenesis, 1983
- RanitidineDrugs, 1982
- Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine.Gut, 1982
- INHIBITION OF PENTAGASTRIN-STIMULATED AND NOCTURNAL GASTRIC SECRETION BY RANITIDINEThe Lancet, 1979